DZ Bank Call 22.5 JEN 21.06.2024/ DE000DJ29HS6 /
2024-05-21 5:04:34 PM | Chg.+0.010 | Bid5:08:50 PM | Ask5:08:50 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
0.580EUR | +1.75% | 0.590 Bid Size: 60,000 |
0.620 Ask Size: 60,000 |
JENOPTIK AG NA O.N. | 22.50 EUR | 2024-06-21 | Call |
GlobeNewswire
05-17
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire
05-01
Jennifer Leggio Joins Tidal Cyber as Chief Operating Officer Amid Strong Business Growth
GlobeNewswire
05-01
Iovance Biotherapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on ...
GlobeNewswire
04-24
Iovance Biotherapeutics to Present Clinical and Translational Data at 2024 ASCO Annual Meeting
GlobeNewswire
04-23
Wind Harvest Surpasses $500K Milestone on Netcapital, Offers Limited-Time Discounted Shares
GlobeNewswire
04-19
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire
04-17
Hain Celestial Announces Fiscal Third Quarter 2024 Results Conference Call and Webcast
GlobeNewswire
04-11
Sharecare teams up with Anthem Blue Cross and Blue Shield on Jump Shot for Health initiative to supp...
GlobeNewswire
04-02
2XO Kentucky Straight Bourbon Whiskey Releases The Kiawah Blend, Renowned Blender Dixon Dedman’s Fou...
GlobeNewswire
03-22
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire
03-04
Iovance Biotherapeutics Announces FDA has Lifted Clinical Hold on the IOV-LUN-202 Registrational Tri...
GlobeNewswire
02-22
Iovance Biotherapeutics to Host Fourth Quarter and Full-Year 2023 Financial Results Conference Call ...
GlobeNewswire
02-21
Weebit Nano demonstrates performance of its ReRAM under extended automotive conditions
GlobeNewswire
02-20
Iovance Biotherapeutics, Inc. Announces Pricing of $211 Million Underwritten Offering of Common Stoc...
GlobeNewswire
02-16
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)